Initiatives to adjust the levels of FKBP51 or its interplay with HSP90 might hold therapeutic significance in treating Alzheimer’s disease, tauopathies, and disorders related to stress. The gene discussed is FKBP4; the disease is early-onset autosomal dominant Alzheimer disease.